<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.103057</article-id><article-id pub-id-type="publisher-id">TCM-42800</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210300000_58456477.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学的金银花治疗过敏性鼻炎作用机制研究
  Study on Mechanism of Lonicerae japonica in Treatment of Allergic Rhinitis Based on Network Pharmacology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曲</surname><given-names>添星</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>结鑫</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>文倩</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>昊前</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>芮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>穆</surname><given-names>永兰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>立明</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>宁夏医科大学药学院；宁夏特色中医药现代化工程技术研究中心，宁夏 银川；宁夏医科大学回医药现代化教育部重点实验室，宁夏 银川</addr-line></aff><aff id="aff3"><addr-line>宁夏医科大学药学院</addr-line></aff><aff id="aff2"><addr-line>宁夏医科大学药学院，宁夏 银川；中国海洋大学医药学院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>04</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>402</fpage><lpage>413</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：基于网络药理学探究金银花治疗过敏性鼻炎的作用机制。方法：通过TCMSP数据库，根据ADME筛选出金银花的活性成分及其靶点，使用Uniprot数据库规范靶点对应的人类基因名；通过Genecards、TTD、OMIM数据库获取过敏性鼻炎主要靶点，利用R语言绘制Venn图得到金银花活性成分作用靶点与过敏性鼻炎的交集靶点；Perl软件整理数据，采用Cytoscape3.7.2软件构建“金银花活性成分–过敏性鼻炎靶点”网络；利用String平台进行蛋白质相互作用分析，构建PPI网络并挖掘网络中潜在的蛋白质功能模块；采用Metascape平台进行GO富集与KEGG富集分析；最后通过Ledock进行分子对接验证。结果：通过TCMSP检索到236个金银花主要化学成分，筛选出23个活性成分，根据Uniprot数据库，排除无对应基因名部分，排除靶点重复部分，共获得活性成分17个，靶点193个；以“allergic rhinitis”为关键词，检索OMIM数据库、GeneCards数据库、TTD数据库的疾病潜在作用靶点，排除重复部分，得到过敏性鼻炎潜在作用靶点2089个，利用R语言绘制Venn图，得到疾病–活性成分共同靶点98个；利用CytoNCA得出Degree前3的活性成分是槲皮素、木犀草素和山柰酚；物种设置为人源性，以0.40为置信区间，构建了节点数98、边数1762、平均节点度36、平均局部聚类系数0.684的PPI网络；GO富集和KEGG富集显示，金银花主要参与的生物学过程包括生物对脂多糖的应答过程(response to lipopolysaccharide)、凋亡细胞通路(apoptotic signaling pathway)、调节细胞黏附(regulation of cell adhesion)、对受伤的应答(response to wounding)、对毒性物质的应答(response to toxic substance)等，参与的通路主要有癌症信号通路(Pathways in cancer)、流体剪切应力与动脉粥样硬化(Fluid shear stress and atherosclerosis)、IL-17信号通路(IL-17signaling pathway)以及癌症蛋白聚糖(Proteoglycans in cancer)等，相关靶点治疗过敏性鼻炎的功能主要富集于转录因子结合(transcription factor binding)、蛋白均二聚活性(protein homodimerization activity)、细胞因子受体结合(cytokine receptor binding)、激酶结合(kinase binding)、蛋白激酶活性(protein kinase activity)等；金银花关键活性成分槲皮素、木犀草素、山柰酚与疾病关键靶点AKT1 (PDB ID: 4EJN)对接亲和力分别为−6.07、−6.91、−5.81 kcal/mol，均 &lt; −5 kcal/mol，结合稳定，验证了网络药理学。结论：金银花治疗过敏性鼻炎的机制具有多靶点、多通路特点，为后续的基础研究提供了思路。
  Objective: To study the mechanism of Lonicerae japonica in the treatment of allergic rhinitis based on network pharmacology. Methods: Obtain the main active chemical components and targets of Lonicerae japonica through TCMSP database according to ADME, use Uniprot database to standardize the gene name of the targets; obtain the main targets of allergic rhinitis through Genecards, TTD, OMIM databases, and use R Language to draw Venn diagram; Perl software organizes data; use Cytoscape 3.7.2 software to construct “Lonicerae japonica active ingredient-allergic rhinitis target” network; use String platform for protein interaction analysis, construct PPI network and explore potential protein functional modules in the network; use Metascape platform for GO enrichment and KEGG enrichment; Finally, Ledock is used for molecular docking verification. Results: 236 main chemical components of Lonicerae japonica were retrieved through TCMSP, and 23 active components were screened out. According to Uniprot database, the part without corresponding gene name and the repeated part of target were excluded. A total of 17 active components and 193 targets were obtained; set “allergicrhinitis” as the key word, search OMIM database, GeneCards database, TTD database for potential disease targets, exclude duplicate parts, get 2089 potential targets for allergic rhinitis, use R language to draw Venn diagram, get disease-active ingredient common target 98 points; use CytoNCA to get the top 3 active ingredients that are quercetin, luteolin, and kaempferol according to Degree; the species is set to human origin, with a confidence interval of 0.40, the number of nodes is 98, the number of edges is 1762, and the average A PPI network with a node degree of 36 and an average local clustering coefficient of 0.684; GO enrichment and KEGG enrichment show that Lonicerae japonica mainly participates in biological processes including biological response to lipopolysaccharide, apoptotic signaling pathway, regulation of cell adhesion, response to wounding, response to toxic substances, etc. The main pathways involved are Pathways in cancer, Fluid shear stress and atherosclerosis, IL-17 signaling pathway and Proteoglycans in cancer, etc. The functions of related targets for the treatment of allergic rhinitis are mainly enriched in transcription factor binding, protein homodimerization activity, cytokine receptor binding, kinase binding, protein kinase activity, etc. The key active ingredients quercetin, luteolin, kaempferol and the key disease target AKT1 (PDBID: 4EJN) docking affinity were −6.07, −6.91, −5.81 kcal/mol, all &lt; −5 kcal/mol, indicating the combination was stable, which verified network pharmacology. Conclusion: The mechanism of Lonicerae japonica in treating allergic rhinitis was characterized by multi-target and multi-pathway, which could provide insights for further experimental study.
 
</p></abstract><kwd-group><kwd>网络药理学，金银花，过敏性鼻炎，分子对接, Network Pharmacology</kwd><kwd> Lonicerae japonica</kwd><kwd> Allergic Rhinitis</kwd><kwd> Molecular Docking</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：基于网络药理学探究金银花治疗过敏性鼻炎的作用机制。方法：通过TCMSP数据库，根据ADME筛选出金银花的活性成分及其靶点，使用Uniprot数据库规范靶点对应的人类基因名；通过Genecards、TTD、OMIM数据库获取过敏性鼻炎主要靶点，利用R语言绘制Venn图得到金银花活性成分作用靶点与过敏性鼻炎的交集靶点；Perl软件整理数据，采用Cytoscape3.7.2软件构建“金银花活性成分–过敏性鼻炎靶点”网络；利用String平台进行蛋白质相互作用分析，构建PPI网络并挖掘网络中潜在的蛋白质功能模块；采用Metascape平台进行GO富集与KEGG富集分析；最后通过Ledock进行分子对接验证。结果：通过TCMSP检索到236个金银花主要化学成分，筛选出23个活性成分，根据Uniprot数据库，排除无对应基因名部分，排除靶点重复部分，共获得活性成分17个，靶点193个；以“allergic rhinitis”为关键词，检索OMIM数据库、GeneCards数据库、TTD数据库的疾病潜在作用靶点，排除重复部分，得到过敏性鼻炎潜在作用靶点2089个，利用R语言绘制Venn图，得到疾病–活性成分共同靶点98个；利用CytoNCA得出Degree前3的活性成分是槲皮素、木犀草素和山柰酚；物种设置为人源性，以0.40为置信区间，构建了节点数98、边数1762、平均节点度36、平均局部聚类系数0.684的PPI网络；GO富集和KEGG富集显示，金银花主要参与的生物学过程包括生物对脂多糖的应答过程(response to lipopolysaccharide)、凋亡细胞通路(apoptotic signaling pathway)、调节细胞黏附(regulation of cell adhesion)、对受伤的应答(response to wounding)、对毒性物质的应答(response to toxic substance)等，参与的通路主要有癌症信号通路(Pathways in cancer)、流体剪切应力与动脉粥样硬化(Fluid shear stress and atherosclerosis)、IL-17信号通路(IL-17signaling pathway)以及癌症蛋白聚糖(Proteoglycans in cancer)等，相关靶点治疗过敏性鼻炎的功能主要富集于转录因子结合(transcription factor binding)、蛋白均二聚活性(protein homodimerization activity)、细胞因子受体结合(cytokine receptor binding)、激酶结合(kinase binding)、蛋白激酶活性(protein kinase activity)等；金银花关键活性成分槲皮素、木犀草素、山柰酚与疾病关键靶点AKT1 (PDB ID: 4EJN)对接亲和力分别为−6.07、−6.91、−5.81 kcal/mol，均 &lt; −5 kcal/mol，结合稳定，验证了网络药理学。结论：金银花治疗过敏性鼻炎的机制具有多靶点、多通路特点，为后续的基础研究提供了思路。</p></sec><sec id="s2"><title>关键词</title><p>网络药理学，金银花，过敏性鼻炎，分子对接</p></sec><sec id="s3"><title>Study on Mechanism of Lonicerae japonica in Treatment of Allergic Rhinitis Based on Network Pharmacology</title><p>Tianxing Qu<sup>1,2</sup>, Jiexin Wang<sup>1</sup>, Wenqian Yang<sup>1</sup>, Haoqian Yan<sup>1</sup>, Rui Wu<sup>1</sup>, Yonglan Mu<sup>1</sup>, Liming Zhang<sup>1,3,4*</sup></p><p><sup>1</sup>School of Pharmacy, Ningxia Medical University, Yinchuan Ningxia</p><p><sup>2</sup>School of Medicine and Pharmacy, Ocean University of China, Qingdao Shandong</p><p><sup>3</sup>Ningxia Research Center for Modernization of Traditional Chinese Medicine Engineering Technology, Yinchuan Ningxia</p><p><sup>4</sup>Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan Ningxia</p><p><img src="//html.hanspub.org/file/18-2270686x5_hanspub.png" /></p><p>Received: Apr. 3<sup>rd</sup>, 2021; accepted: May 21<sup>st</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/18-2270686x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To study the mechanism of Lonicerae japonica in the treatment of allergic rhinitis based on network pharmacology. Methods: Obtain the main active chemical components and targets of Lonicerae japonica through TCMSP database according to ADME, use Uniprot database to standardize the gene name of the targets; obtain the main targets of allergic rhinitis through Genecards, TTD, OMIM databases, and use R Language to draw Venn diagram; Perl software organizes data; use Cytoscape 3.7.2 software to construct “Lonicerae japonica active ingredient-allergic rhinitis target” network; use String platform for protein interaction analysis, construct PPI network and explore potential protein functional modules in the network; use Metascape platform for GO enrichment and KEGG enrichment; Finally, Ledock is used for molecular docking verification. Results: 236 main chemical components of Lonicerae japonica were retrieved through TCMSP, and 23 active components were screened out. According to Uniprot database, the part without corresponding gene name and the repeated part of target were excluded. A total of 17 active components and 193 targets were obtained; set “allergicrhinitis” as the key word, search OMIM database, GeneCards database, TTD database for potential disease targets, exclude duplicate parts, get 2089 potential targets for allergic rhinitis, use R language to draw Venn diagram, get disease-active ingredient common target 98 points; use CytoNCA to get the top 3 active ingredients that are quercetin, luteolin, and kaempferol according to Degree; the species is set to human origin, with a confidence interval of 0.40, the number of nodes is 98, the number of edges is 1762, and the average A PPI network with a node degree of 36 and an average local clustering coefficient of 0.684; GO enrichment and KEGG enrichment show that Lonicerae japonica mainly participates in biological processes including biological response to lipopolysaccharide, apoptotic signaling pathway, regulation of cell adhesion, response to wounding, response to toxic substances, etc. The main pathways involved are Pathways in cancer, Fluid shear stress and atherosclerosis, IL-17 signaling pathway and Proteoglycans in cancer, etc. The functions of related targets for the treatment of allergic rhinitis are mainly enriched in transcription factor binding, protein homodimerization activity, cytokine receptor binding, kinase binding, protein kinase activity, etc. The key active ingredients quercetin, luteolin, kaempferol and the key disease target AKT1 (PDBID: 4EJN) docking affinity were −6.07, −6.91, −5.81 kcal/mol, all &lt; −5 kcal/mol, indicating the combination was stable, which verified network pharmacology. Conclusion: The mechanism of Lonicerae japonica in treating allergic rhinitis was characterized by multi-target and multi-pathway, which could provide insights for further experimental study.</p><p>Keywords:Network Pharmacology, Lonicerae japonica, Allergic Rhinitis, Molecular Docking</p><disp-formula id="hanspub.42800-formula19"><graphic xlink:href="//html.hanspub.org/file/18-2270686x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/18-2270686x8_hanspub.png" /> <img src="//html.hanspub.org/file/18-2270686x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>过敏性鼻炎(Allergic Rhinitis, AR)，也称变应性鼻炎，是一种由基因与环境因素互相作用而引起的变态反应性疾病，临床以鼻塞、流清涕、鼻痒及黏膜苍白水肿为特点，属于中医“过敏性鼻炎”“鼻鼽”“鼽嚏”与“鼽鼻”等范畴。随着公共环境变化，过敏性鼻炎在全球发病率逐年增长，保守估计在5亿以上。目前临床主要采取避免接触变应原、环境刺激物、药物治疗、免疫疗法、手术疗法等，虽具有一定效果，但停药后易反复且不能根治 [<xref ref-type="bibr" rid="hanspub.42800-ref1">1</xref>]，需要挖掘出更多有效疗法。从过敏性鼻炎的治疗来讲，中医中药的优势逐渐受到医学界的重视。随着中医药治疗过敏性鼻炎的临床研究日益增多，许多有效的中药复方被挖掘，同时在现代中药药理研究学的辅助下，临床也发现了一大批具有发展前景的单味中药和中药有效成分 [<xref ref-type="bibr" rid="hanspub.42800-ref2">2</xref>]，这其中包括金银花及其有效成分。</p><p>金银花(Lonicera japonica Thunb.)为忍冬科(Caprifoliaceae)植物忍冬的干燥花蕾或初开的花，药用历史较为悠久，为常用中药之一。据报道，金银花常作为清热解毒的良药，具有很好的抗炎活性 [<xref ref-type="bibr" rid="hanspub.42800-ref3">3</xref>]。目前，对于过敏性鼻炎的中医治疗未形成完整体系，金银花尽管能起到一定疗效，但其作用机制仍不明确，药效成分和核心靶点蛋白有待探究。</p><p>网络药理学是近年来提出的一种新思想。它是在现代药理学 [<xref ref-type="bibr" rid="hanspub.42800-ref4">4</xref>] 研究的基础上提出的一种新的药物设计与开发方法和策略。网络药理学促进了医学研究从之前的“单一靶点、单一药物”向“多靶点、多药物”这一新模式的转变 [<xref ref-type="bibr" rid="hanspub.42800-ref5">5</xref>]，为新药开发提供了新途径和新策略。因此，本文尝试通过网络药理学的理论及方法研究金银花治疗过敏性鼻炎的作用机制，确定金银花的核心成分与核心靶点，为进一步的实验研究及临床运用提供理论依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 金银花活性成分筛选</title><p>通过中药系统药理学数据库与分析平台 [<xref ref-type="bibr" rid="hanspub.42800-ref6">6</xref>] (TCMSP, Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, http://lsp.nwu.edu.cn/tcmsp.php)，在“Herbname”词条框中输入“金银花”，获取金银花条目，点击进入并获取分子信息，包括化学成分的ID与分子名称(Mol ID、Molecule Name)、口服生物利用度(OB)、类药性(DL)等。以OB ≥ 30%和DL ≥ 0.18作为条件筛选金银花的活性成分。</p></sec><sec id="s6_2"><title>2.2. 金银花活性成分相关蛋白靶点获取</title><p>根据筛选得到的活性成分，在TCMSP中点击“Related Targets”，获取成分的“Targets Information”，得到该成分作用的靶蛋白名(Target name)。在Uniprot (http://www.uniprot.org/)中，使用Uniprot KB检索功能，在检索框中输入靶蛋白名，检索条件为“organism：homo sapiens”和“reviewed：yes”，获取基因名(gene name)和Uniprot ID。检索结果以.xlsx格式导出，保留不同成分作用蛋白靶点基因条目，包括金银花活性成分对应人类的相关蛋白靶点基因及其对应Uniprot ID。</p></sec><sec id="s6_3"><title>2.3. 过敏性鼻炎相关靶点基因获取</title><p>通过Genecards (https://www.genecards.org/)、TTD (https://db.idrblab.org/ttd/)、OMIM (http://www.omim.org/)数据库，以“allergic rhinitis”为关键词检索过敏性鼻炎相关基因，分别获取过敏性鼻炎相关基因和蛋白靶点信息，对数据进行整理合并，并删除重复值(相同的Gene简称)，得到包括基因、对应靶点名称(target name)和UN结果(Uniprot)的Excel文件。</p></sec><sec id="s6_4"><title>2.4. 金银花与过敏性鼻炎作用靶点Venn图构建</title><p>利用R语言软件将过敏性鼻炎与金银花的活性成分靶点进行匹配，得到疾病与药对靶点交集的Venn图，并以txt格式导出共同靶点。</p></sec><sec id="s6_5"><title>2.5. 金银花治疗过敏性鼻炎的“活性成分–作用靶点”网络构建</title><p>根据金银花抗过敏性鼻炎的“活性成分–作用靶点”，用Perl软件进行整理，运用Cytoscape3.7.2软件，得到金银花治疗过敏性鼻炎的“活性成分–作用靶点”调控网络，利用CytoNCA插件，得出活性成分Degree排名。</p></sec><sec id="s6_6"><title>2.6. 交集蛋白靶点相互作用网络构建</title><p>检索String数据库 [<xref ref-type="bibr" rid="hanspub.42800-ref7">7</xref>] (https://string-db.org/)，点击“Multiple Proteins”，在“List Of Names”词条框中，输入交集靶点，并在“Organism”词条框中选择“Homosapiens”，点击“SEARCH”，点击“CONTINUE”，获取交集蛋白靶点的相互作用关系。</p></sec><sec id="s6_7"><title>2.7. 交集靶点GO富集和KEGG富集分析</title><p>使用Metascape平台 [<xref ref-type="bibr" rid="hanspub.42800-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref9">9</xref>] 对金银花活性成分治疗过敏性鼻炎靶点进行GO富集分析，获取其生物过程(biological process, BP)、分子功能(Molecular Function, MF)、细胞组成(Cellular Component, CC)，并进行KEGG富集分析。</p></sec><sec id="s6_8"><title>2.8. 金银花治疗过敏性鼻炎的分子对接</title><p>利用分子对接技术研究金银花的活性成分及过敏性鼻炎相关靶蛋白的相互作用，在一定程度上能够说明活性分子治疗过敏性鼻炎的作用机制及结合活性 [<xref ref-type="bibr" rid="hanspub.42800-ref10">10</xref>]。对PPI预测结果中的核心靶点及金银花中Degree值排在前三位的活性成分进行分子模拟对接，在PDB数据库检索并下载靶点的蛋白3D结构，利用ZINC数据库下载活性成分的3D结构，将其导入PyMOL、AutoDock Tools软件进行预处理，然后将受体和配体输入Ledock进行分子对接。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 金银花活性成分</title><p>通过TCMSP检索到236个金银花化合物，筛选出23个活性化合物，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Main active ingredients in Lonicerae japonic</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >编号</th><th align="center" valign="middle" >MoI ID</th><th align="center" valign="middle" >分子名称</th><th align="center" valign="middle" >OB%</th><th align="center" valign="middle" >DL</th></tr></thead><tr><td align="center" valign="middle" >JYH-01</td><td align="center" valign="middle" >MOL001494</td><td align="center" valign="middle" >Mandenol</td><td align="center" valign="middle" >42.00</td><td align="center" valign="middle" >0.19</td></tr><tr><td align="center" valign="middle" >JYH-02</td><td align="center" valign="middle" >MOL001495</td><td align="center" valign="middle" >Ethyl linolenate<sup> </sup></td><td align="center" valign="middle" >46.10<sup> </sup></td><td align="center" valign="middle" >0.20</td></tr><tr><td align="center" valign="middle" >JYH-03</td><td align="center" valign="middle" >MOL002707</td><td align="center" valign="middle" >phytofluene<sup> </sup></td><td align="center" valign="middle" >43.18<sup> </sup></td><td align="center" valign="middle" >0.50</td></tr><tr><td align="center" valign="middle" >JYH-04</td><td align="center" valign="middle" >MOL002914</td><td align="center" valign="middle" >Eriodyctiol (flavanone)<sup> </sup></td><td align="center" valign="middle" >41.35</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >JYH-05</td><td align="center" valign="middle" >MOL003006</td><td align="center" valign="middle" >(-)-(3R,8S,9R,9aS,10aS)-9-ethenyl-8-(beta-D-glucopyranosyloxy)-2,3,9,9a,10,10a-hexahydro-5-oxo-5H,8H-pyrano[4,3-d]oxazolo[3,2-a]pyridine-3-carboxylic acid_qt<sup> </sup></td><td align="center" valign="middle" >87.47</td><td align="center" valign="middle" >0.23</td></tr><tr><td align="center" valign="middle" >JYH-06</td><td align="center" valign="middle" >MOL003014</td><td align="center" valign="middle" >secologanicdibutylacetal_qt</td><td align="center" valign="middle" >53.65</td><td align="center" valign="middle" >0.29</td></tr><tr><td align="center" valign="middle" >JYH-07</td><td align="center" valign="middle" >MOL002773</td><td align="center" valign="middle" >beta-carotene</td><td align="center" valign="middle" >37.18</td><td align="center" valign="middle" >0.58</td></tr><tr><td align="center" valign="middle" >JYH-08</td><td align="center" valign="middle" >MOL003036</td><td align="center" valign="middle" >ZINC03978781</td><td align="center" valign="middle" >43.83</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >JYH-09</td><td align="center" valign="middle" >MOL003044</td><td align="center" valign="middle" >Chryseriol</td><td align="center" valign="middle" >35.85</td><td align="center" valign="middle" >0.27</td></tr><tr><td align="center" valign="middle" >JYH-10</td><td align="center" valign="middle" >MOL003059</td><td align="center" valign="middle" >kryptoxanthin</td><td align="center" valign="middle" >47.25</td><td align="center" valign="middle" >0.57</td></tr><tr><td align="center" valign="middle" >JYH-11</td><td align="center" valign="middle" >MOL003062</td><td align="center" valign="middle" >4,5’-Retro-.beta.,.beta.-Carotene-3,3’-dione, 4’,5’-didehydro-</td><td align="center" valign="middle" >31.22</td><td align="center" valign="middle" >0.55</td></tr><tr><td align="center" valign="middle" >JYH-12</td><td align="center" valign="middle" >MOL003095</td><td align="center" valign="middle" >5-hydroxy-7-methoxy-2-(3,4,5-trimethoxyphenyl)chromone</td><td align="center" valign="middle" >51.96</td><td align="center" valign="middle" >0.41</td></tr><tr><td align="center" valign="middle" >JYH-13</td><td align="center" valign="middle" >MOL003101</td><td align="center" valign="middle" >7-epi-Vogeloside</td><td align="center" valign="middle" >46.13</td><td align="center" valign="middle" >0.58</td></tr><tr><td align="center" valign="middle" >JYH-14</td><td align="center" valign="middle" >MOL003108</td><td align="center" valign="middle" >Caeruloside C</td><td align="center" valign="middle" >55.64</td><td align="center" valign="middle" >0.73</td></tr><tr><td align="center" valign="middle" >JYH-15</td><td align="center" valign="middle" >MOL003111</td><td align="center" valign="middle" >Centauroside_qt</td><td align="center" valign="middle" >55.79</td><td align="center" valign="middle" >0.50</td></tr><tr><td align="center" valign="middle" >JYH-16</td><td align="center" valign="middle" >MOL003117</td><td align="center" valign="middle" >IoniceracetalidesB_qt</td><td align="center" valign="middle" >61.19</td><td align="center" valign="middle" >0.19</td></tr><tr><td align="center" valign="middle" >JYH-17</td><td align="center" valign="middle" >MOL003124</td><td align="center" valign="middle" >XYLOSTOSIDINE</td><td align="center" valign="middle" >43.17</td><td align="center" valign="middle" >0.64</td></tr><tr><td align="center" valign="middle" >JYH-18</td><td align="center" valign="middle" >MOL003128</td><td align="center" valign="middle" >dinethylsecologanoside</td><td align="center" valign="middle" >48.46</td><td align="center" valign="middle" >0.48</td></tr><tr><td align="center" valign="middle" >JYH-19</td><td align="center" valign="middle" >MOL000358</td><td align="center" valign="middle" >beta-sitosterol</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr><tr><td align="center" valign="middle" >JYH-20</td><td align="center" valign="middle" >MOL000422</td><td align="center" valign="middle" >kaempferol</td><td align="center" valign="middle" >41.88</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >JYH-21</td><td align="center" valign="middle" >MOL000449</td><td align="center" valign="middle" >Stigmasterol</td><td align="center" valign="middle" >43.83</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >JYH-22</td><td align="center" valign="middle" >MOL000006</td><td align="center" valign="middle" >luteolin</td><td align="center" valign="middle" >36.16</td><td align="center" valign="middle" >0.25</td></tr><tr><td align="center" valign="middle" >JYH-23</td><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >46.43</td><td align="center" valign="middle" >0.28</td></tr></tbody></table></table-wrap><p>表1. 金银花活性成分基本信息</p></sec><sec id="s7_2"><title>3.2. 金银花活性成分对应靶蛋白</title><p>通过TCMSP分别获取23个成分作用的相关靶点蛋白名称，根据Uniprot数据库筛选活性成分并为其添加相关靶标，排除无对应基因名部分，排除靶点重复部分，共获得活性成分17个，靶点193个。</p></sec><sec id="s7_3"><title>3.3. 过敏性鼻炎相关靶点</title><p>以“allergic rhinitis”为关键词，检索Genecards数据库、TTD数据库、OMIM数据库的疾病潜在作用靶点，排除重复部分，得到过敏性鼻炎潜在作用靶点2089个。</p></sec><sec id="s7_4"><title>3.4. 金银花与过敏性鼻炎Venn图构建</title><p>利用R语言软件将过敏性鼻炎与金银花的活性成分靶点进行匹配，得到疾病与药对靶点98个见图1，共同靶点见表2。</p><p>图1. 药物(JYH)与疾病(AR)靶点的Venn图</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> 98 Latent targets of 17 active ingredient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="7"  >潜在靶点</th></tr></thead><tr><td align="center" valign="middle" >PTGS1</td><td align="center" valign="middle" >HMOX1</td><td align="center" valign="middle" >ADRB2</td><td align="center" valign="middle" >TNF</td><td align="center" valign="middle" >EGFR</td><td align="center" valign="middle" >MET</td><td align="center" valign="middle" >IL1A</td></tr><tr><td align="center" valign="middle" >PTGS2</td><td align="center" valign="middle" >CYP3A4</td><td align="center" valign="middle" >CHRM3</td><td align="center" valign="middle" >MAPK8</td><td align="center" valign="middle" >BCL2L1</td><td align="center" valign="middle" >EGF</td><td align="center" valign="middle" >MPO</td></tr><tr><td align="center" valign="middle" >PIK3CG</td><td align="center" valign="middle" >CYP1A2</td><td align="center" valign="middle" >HTR2A</td><td align="center" valign="middle" >STAT1</td><td align="center" valign="middle" >MMP9</td><td align="center" valign="middle" >ODC1</td><td align="center" valign="middle" >NFE2L2</td></tr><tr><td align="center" valign="middle" >DPP4</td><td align="center" valign="middle" >CTNNB1</td><td align="center" valign="middle" >ADRA1A</td><td align="center" valign="middle" >CYP1A1</td><td align="center" valign="middle" >MAPK1</td><td align="center" valign="middle" >SOD1</td><td align="center" valign="middle" >PARP1</td></tr><tr><td align="center" valign="middle" >ESR1</td><td align="center" valign="middle" >MYC</td><td align="center" valign="middle" >CHRM2</td><td align="center" valign="middle" >ICAM1</td><td align="center" valign="middle" >IL10</td><td align="center" valign="middle" >HIF1A</td><td align="center" valign="middle" >CXCL11</td></tr><tr><td align="center" valign="middle" >AKT1</td><td align="center" valign="middle" >GJA1</td><td align="center" valign="middle" >ADRA1B</td><td align="center" valign="middle" >SELE</td><td align="center" valign="middle" >IL6</td><td align="center" valign="middle" >IL1B</td><td align="center" valign="middle" >CXCL2</td></tr><tr><td align="center" valign="middle" >VEGFA</td><td align="center" valign="middle" >PGR</td><td align="center" valign="middle" >SLC6A4</td><td align="center" valign="middle" >VCAM1</td><td align="center" valign="middle" >TP53</td><td align="center" valign="middle" >CCL2</td><td align="center" valign="middle" >DCAF5</td></tr><tr><td align="center" valign="middle" >BCL2</td><td align="center" valign="middle" >NOS2</td><td align="center" valign="middle" >CHRNA7</td><td align="center" valign="middle" >GSTP1</td><td align="center" valign="middle" >NFKBIA</td><td align="center" valign="middle" >PTGER3</td><td align="center" valign="middle" >PPARA</td></tr><tr><td align="center" valign="middle" >CASP9</td><td align="center" valign="middle" >AR</td><td align="center" valign="middle" >PRKCA</td><td align="center" valign="middle" >AHR</td><td align="center" valign="middle" >ERBB2</td><td align="center" valign="middle" >CXCL8</td><td align="center" valign="middle" >CRP</td></tr><tr><td align="center" valign="middle" >MMP2</td><td align="center" valign="middle" >PPARG</td><td align="center" valign="middle" >TGFB1</td><td align="center" valign="middle" >GSTM1</td><td align="center" valign="middle" >BIRC5</td><td align="center" valign="middle" >NOS3</td><td align="center" valign="middle" >CXCL10</td></tr><tr><td align="center" valign="middle" >JUN</td><td align="center" valign="middle" >MAPK14</td><td align="center" valign="middle" >PON1</td><td align="center" valign="middle" >SLPI</td><td align="center" valign="middle" >IL2</td><td align="center" valign="middle" >PLAT</td><td align="center" valign="middle" >CHUK</td></tr><tr><td align="center" valign="middle" >CASP3</td><td align="center" valign="middle" >GSK3B</td><td align="center" valign="middle" >ACHE</td><td align="center" valign="middle" >ADRA2A</td><td align="center" valign="middle" >IFNG</td><td align="center" valign="middle" >THBD</td><td align="center" valign="middle" >SPP1</td></tr><tr><td align="center" valign="middle" >CASP8</td><td align="center" valign="middle" >KCNH2</td><td align="center" valign="middle" >RELA</td><td align="center" valign="middle" >PLAU</td><td align="center" valign="middle" >IL4</td><td align="center" valign="middle" >SERPINE1</td><td align="center" valign="middle" >IRF1</td></tr><tr><td align="center" valign="middle" >MMP1</td><td align="center" valign="middle" >ESR2</td><td align="center" valign="middle" >IKBKB</td><td align="center" valign="middle" >LTA4H</td><td align="center" valign="middle" >CD40LG</td><td align="center" valign="middle" >PTEN</td><td align="center" valign="middle" >ERBB3</td></tr></tbody></table></table-wrap><p>表2. 17个活性成分作用的98个潜在靶点</p></sec><sec id="s7_5"><title>3.5. 金银花治疗过敏性鼻炎的“活性成分–作用靶点”网络构建</title><p>利用Perl软件整理数据，导入Cytoscape软件，构建金银花抗过敏性鼻炎的“活性成分–作用靶点”调控网络。其中右侧为药物靶点，左侧为活性成分，见图2。利用CytoNCA得出Degree前3的活性成分是槲皮素、木犀草素和山柰酚。</p><p>图2. 金银花治疗过敏性鼻炎的“活性成分–作用靶点”网络</p><p>图3. 药物(JYH)与疾病(AR) PPI图</p></sec><sec id="s7_6"><title>3.6. 金银花与过敏性鼻炎的靶点蛋白互作网络(PPI)</title><p>将“3.4”项中获得的交集靶点导入String网站，物种设置为人源性，以交互作用证据类型为边，以置信区间0.40为要求，获得蛋白互作网络图，导出PPI网络图(见图3)，其中节点数98、边数1762、平均节点度36、平均局部聚类系数0.684；黄绿色连线表示文字挖掘、黑色连线表示共表达、灰色连线表示蛋白质同源性、荧光绿连线表示基因邻里、红色连线表示基因融合、晶蓝色连线表示基因共现、天蓝色连线表示数据库挖掘、粉紫色连线表示实验获得。</p></sec><sec id="s7_7"><title>3.7. 金银花与过敏性鼻炎的GO富集分析和KEGG通路富集分析</title><p>应用Metascape数据平台对金银花治疗过敏性鼻炎相关靶点进行信号通路分析，借助Excel对结果可视化。由结果可见多个靶点的功能与过敏性鼻炎的产生密不可分。金银花主要参与的生物学过程包括生物对脂多糖的应答过程(response to lipopolysaccharide)、凋亡细胞通路(apoptotic signaling pathway)、调节细胞黏附(regulation of cell adhesion)、对受伤的应答(response to wounding)、对毒性物质的应答(response to toxic substance)、见图4 (A)；相关靶点治疗过敏性鼻炎的功能主要富集于转录因子结合(transcription factor binding)、蛋白均二聚活性(protein homodimerization activity)、细胞因子受体结合(cytokine receptor binding)、激酶结合(kinase binding)、蛋白激酶活性(protein kinase activity)等，见图5 (B)；细胞成分主要富集于膜筏(membrane raft)等，见图6 (C)；参与的通路主要有癌症信号通路(pathways in cancer)、流体剪切应力与动脉粥样硬化(fluid shear stress and atherosclerosis)、IL-17信号通路(IL-17 signaling pathway)以及癌症蛋白聚糖(proteoglycans in cancer)等，见图7 (D)。</p><p>图4. 药物(JYH)与疾病(AR) GO-BP富集分析</p></sec><sec id="s7_8"><title>3.8. 金银花治疗过敏性鼻炎分子对接结果</title><p>为了验证金银花有效组分与相关靶标关系，剖析药物–靶点间的分子作用机制，根据“3.5”及“3.6”的结果，本研究选择了选择相关度最高的槲皮素、木犀草素、山柰酚和AKT1 (PDB ID: 4EJN)进行分子对接。目前尚无分子对接的评价标准，以自由结合能 ≤ −5.0 kcal/mol作为评定标准 [<xref ref-type="bibr" rid="hanspub.42800-ref11">11</xref>]。根据Ledock自动打分，槲皮素、木犀草素、山柰酚与AKT1 (PDB ID: 4EJN)之间的自由结合能为−6.07、−6.91、−5.81 kcal/mol，这说明槲皮素、木犀草素、山柰酚与AKT1 (PDB ID: 4EJN)紧密结合，证实预测结果的可靠性，结果见表3。</p><p>图5. 药物(JYH)与疾病(AR) GO-MF富集分析</p><p>图6. 药物(JYH)与疾病(AR) GO-CC富集分析</p><p>图7. 药物(JYH)与疾病(AR) KEGG富集分析</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Molecular docking of key compounds and key protein targe</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >关键化合物</th><th align="center" valign="middle" >关键靶蛋白</th><th align="center" valign="middle" >PDB ID</th><th align="center" valign="middle" >对接亲和力(kcal/mol)</th></tr></thead><tr><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle"  rowspan="3"  >AKT1</td><td align="center" valign="middle"  rowspan="3"  >4EJN</td><td align="center" valign="middle" >−6.07</td></tr><tr><td align="center" valign="middle" >luteolin</td><td align="center" valign="middle" >−6.91</td></tr><tr><td align="center" valign="middle" >kaempferol</td><td align="center" valign="middle" >−5.81</td></tr></tbody></table></table-wrap><p>表3. 关键化合物与关键靶蛋白分子对接结果</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>过敏性鼻炎，现代医学认为是过敏体质人群接触外界抗原后所引起的由免疫球蛋白IgE介导，通过释放组胺或其它化学活性物质诱发的鼻黏膜I型变态反应；在祖国医学中，过敏性鼻炎在病因上多认为肾阳不足，肺脾虚弱，温煦失施，外感邪气乘虚而入所致，临床以反复鼻痒、打喷嚏、流清涕、鼻塞为主要症状；目前，各种疗法只是对症处理，并不能从根本上解决问题，其发病机制在医学上尚没有达成一致认识，各种学说(过敏性鼻炎与炎症介质关系学说、过敏性鼻炎与Th细胞平衡学说、过敏性鼻炎与IgE及其受体关系学说、过敏性鼻炎与Th17细胞学说、过敏性鼻炎与Th9细胞学说、过敏性鼻炎与IL-33关系学说等)都从不同角度进行了初步探索 [<xref ref-type="bibr" rid="hanspub.42800-ref12">12</xref>]，而网络药理学研究的多靶点、多通路可验证过敏性鼻炎的各种学说。</p><p>本文对金银花活性成分的作用靶点进行筛选，并与过敏性鼻炎疾病的相关靶点取交集，筛选出金银花治疗过敏性鼻炎的活性成分–靶点–疾病网络，对网络中的靶点进行蛋白质相互作用分析及多种富集分析，并通过分子对接予以验证。</p><p>结果表明，金银花的17个活性成分与过敏性鼻炎这一疾病具有98个共同靶点，关键活性成分是槲皮素、木犀草素与山柰酚，核心靶点是AKT1，虽然金银花治疗过敏性鼻炎研究较少，但槲皮素 [<xref ref-type="bibr" rid="hanspub.42800-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref14">14</xref>]、木犀草素 [<xref ref-type="bibr" rid="hanspub.42800-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref16">16</xref>]、山柰酚 [<xref ref-type="bibr" rid="hanspub.42800-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref19">19</xref>] 已经被证实具有抗过敏性鼻炎的活性，AKT1被认为是治疗过敏性鼻炎的靶点 [<xref ref-type="bibr" rid="hanspub.42800-ref20">20</xref>]，网络药理学分析后则扩大了活性成分与作用靶点的范围；通过交集靶点成功构建了节点数98、边数1762、平均节点度36、平均局部聚类系数0.684的PPI网络。GO富集和KEGG富集显示，金银花主要参与的生物学过程包括生物对脂多糖的应答过程(response to lipopolysaccharide)、凋亡细胞通路(apoptotic signaling pathway)、调节细胞黏附(regulation of cell adhesion)、对受伤的应答(response to wounding)、对毒性物质的应答(response to toxic substance)等，前二者已被证实 [<xref ref-type="bibr" rid="hanspub.42800-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref22">22</xref>]，后三者为新发现的生物学过程；参与的通路主要有癌症信号通路(Pathways in cancer)、流体剪切应力与动脉粥样硬化(Fluid shear stress and atherosclerosis)、IL-17信号通路(IL-17signaling pathway)以及癌症蛋白聚糖(Proteoglycans in cancer)等，相关靶点治疗过敏性鼻炎的功能主要富集于转录因子结合(transcription factor binding)、蛋白均二聚活性(protein homodimerization activity)、细胞因子受体结合(cytokine receptor binding)、激酶结合(kinase binding)、蛋白激酶活性(protein kinase activity)等，而IL-17信号通路已被证实是治疗过敏性鼻炎关键通路 [<xref ref-type="bibr" rid="hanspub.42800-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.42800-ref25">25</xref>]；关键活性成分槲皮素、木犀草素、山柰酚与疾病关键靶点AKT1 (PDB ID: 4EJN)对接亲和力分别为−6.07、−6.91、−5.81 kcal/mol，均&lt; −5 kcal/mol，结合稳定，证明了网络药理学的可靠性。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本研究通过网络药理方法探讨金银花治疗过敏性鼻炎的作用机制，确定金银花治疗过敏性鼻炎的关键活性成分、核心靶点，知晓主要生物过程、分子功能、细胞组成及通路，为后续基础研究提供了方向。</p></sec><sec id="s10"><title>基金项目</title><p>宁夏医科大学国内一流学科中医药学(NXYLXK2017A06)；宁夏高校大学生创新创业训练计划资助。</p></sec><sec id="s11"><title>文章引用</title><p>曲添星,王结鑫,杨文倩,闫昊前,吴 芮,穆永兰,张立明. 基于网络药理学的金银花治疗过敏性鼻炎作用机制研究Study on Mechanism of Lonicerae japonica in Treatment of Allergic Rhinitis Based on Network Pharmacology[J]. 中医学, 2021, 10(03): 402-413. https://doi.org/10.12677/TCM.2021.103057</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42800-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">马春, 李淑玲, 郝如彬, 等. 中医药治疗变应性鼻炎的作用机制及研究进展[J]. 中国中医基础医学杂志, 2019, 25(10): 1473-1476.</mixed-citation></ref><ref id="hanspub.42800-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">苏梦可, 杨一民. 儿童变应性鼻炎中医治疗述评[J]. 江西中医药, 2020, 51(8): 74-76.</mixed-citation></ref><ref id="hanspub.42800-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">杜叶青, 段治康, 董舒卉, 等. 基于网络药理学的金银花活性成分抗炎作用机制的研究[J]. 中国药物化学杂志, 2019, 29(2): 96-102.</mixed-citation></ref><ref id="hanspub.42800-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">李娜, 张新庄, 王俨如. 基于网络药理学的通塞脉片治疗耳硬化症的作用机制[J]. 中国中药杂志, 2016(9): 1706-1712.</mixed-citation></ref><ref id="hanspub.42800-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">林卫东, 胡靖敏, 梁生旺, 等. 葛根改善胰岛素抵抗的网络药理学研究[J]. 中药材, 2016, 39(7): 1628-1632.</mixed-citation></ref><ref id="hanspub.42800-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ru, J., Li, P., Wang, J., et al. (2014) TCMSP: A Database of Systems Pharmacology for Drug Discovery from Herbal Medicines. Journal of Cheminformatics, 6, Article No. 13. &lt;br&gt;https://doi.org/10.1186/1758-2946-6-13</mixed-citation></ref><ref id="hanspub.42800-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Szklarczyk, D., Gable, A.L. and Lyon, D. (2019) STRING v11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets. Nucleic Acids Research, 47, D607-D613. &lt;br&gt;https://doi.org/10.1093/nar/gky1131</mixed-citation></ref><ref id="hanspub.42800-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Tripathi, S., Pohl, M.O., Zhou, Y., et al. (2015) Meta- and Orthogonal Integration of Influenza “OMICs” Data Defines a Role for UBR4 in Virus Budding. Cell Host &amp; Microbe, 18, 723-735. &lt;br&gt;https://doi.org/10.1016/j.chom.2015.11.002</mixed-citation></ref><ref id="hanspub.42800-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., Zhou, B., Pache, L., et al. (2019) Metascape Provides a Biologistoriented Resource for the Analysis of Systems-Level Datasets. Nature Communications, 10, Article No. 1523. &lt;br&gt;https://doi.org/10.1038/s41467-019-09234-6</mixed-citation></ref><ref id="hanspub.42800-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">张丹, 董一珠, 吕锦涛, 等. 基于网络药理学与分子对接方法探讨昆明山海棠的毒性机制[J]. 北京中医药大学学报, 2019, 42(12): 1006-1015.</mixed-citation></ref><ref id="hanspub.42800-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">徐森楠, 庄莉, 翟园园, 等. 基于网络药理学研究二至丸防治骨质疏松症的物质基础与作用机制[J]. 中国药学杂志, 2018, 53(22): 1913-1920.</mixed-citation></ref><ref id="hanspub.42800-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">汪晓. 苍耳子对小鼠过敏性鼻炎模型的治疗及作用机制研究[D]: [硕士学位论文]. 长春: 长春中医药大学, 2018.</mixed-citation></ref><ref id="hanspub.42800-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sagit, M., Polat, H., Gurgen, S.G., et al. (2017) Effectiveness of Quercetin in an Experimental Rat Model of Allergic Rhinitis. European Archives of Oto-Rhino-Laryngology, 274, 3087-3095. &lt;br&gt;https://doi.org/10.1007/s00405-017-4602-z</mixed-citation></ref><ref id="hanspub.42800-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kashiwabara, M., Asano, K., Mizuyoshi, T., et al. (2016) Suppression of Neuropeptide Production by Quercetin in Allergic Rhinitis Model Rats. BMC Complementary and Alternative Medicine, 16, Article No. 132.  
&lt;br&gt;https://doi.org/10.1186/s12906-016-1123-z</mixed-citation></ref><ref id="hanspub.42800-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Liang, K.-L., Yu, S.-J., Huang, W.-C. and Yen, H.-R. (2020) Luteolin Attenuates Allergic Nasal Inflammation via Inhibition of Interleukin-4 in an Allergic Rhinitis Mouse Model and Peripheral Blood From Human Subjects with Allergic Rhinitis. Frontiers in Pharmacology, 11. &lt;br&gt;https://doi.org/10.3389/fphar.2020.00291</mixed-citation></ref><ref id="hanspub.42800-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Jang, T.Y., Jung, A.-Y., Kyung, T.-S., et al. (2017) Anti-Allergic Effect of Luteolin in Mice with Allergic Asthma and Rhinitis. Central-European Journal of Immunology, 42, 24-29. &lt;br&gt;https://doi.org/10.5114/ceji.2017.67315</mixed-citation></ref><ref id="hanspub.42800-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">周运江. 山柰酚对过敏性鼻炎体内外的影响及相关机制的实验研究[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2016.</mixed-citation></ref><ref id="hanspub.42800-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">周运江, 王虎, 李丽, 等. 山柰酚对卵清蛋白诱导豚鼠过敏性鼻炎的保护作用[J]. 中成药, 2016, 38(1): 24-29.</mixed-citation></ref><ref id="hanspub.42800-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Oh, H.-A., Han, N.-R., Kim, M.-J., et al. (2013) Evaluation of the Effect of Kaempferol in a Murine Allergic Rhinitis Model. European Journal of Pharmacology, 718, 48-56. &lt;br&gt;https://doi.org/10.1016/j.ejphar.2013.08.045</mixed-citation></ref><ref id="hanspub.42800-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">许戈, 谢枪, 周红宇. 血清miR-375及血液中靶基因在过敏性鼻炎患者治疗前后的表达变化及意义[J]. 中南大学学报(医学版), 2019, 44(7): 767-774.</mixed-citation></ref><ref id="hanspub.42800-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., Wang, H., Sui, H., et al. (2016) Inhibitory Effect of Baicalin on Allergic Response in Ovalbumin-Induced Allergic Rhinitis Guinea Pigs and Lipopolysaccharide-Stimulated Human Mast Cells. Inflammation Research, 65, 603-612. &lt;br&gt;https://doi.org/10.1007/s00011-016-0943-0</mixed-citation></ref><ref id="hanspub.42800-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">胡美玲, 黄昌群. 生存素调控季节性变应性鼻炎患者鼻黏膜CD4~+T细胞凋亡的机制[J]. 国际耳鼻咽喉头颈外科杂志, 2020, 44(6): 323-327.</mixed-citation></ref><ref id="hanspub.42800-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Xue, K., Zheng, Y., et al. (2019) RORA Overexpression Alleviates Nasal Mucosal Injury and Enhances Red Blood Cell Immune Adhesion Function in a Mouse Model of Allergic Rhinitis via Inactivation of the Wnt/β-Catenin Signaling Pathway. International Archives of Allergy and Immunology, 180, 79-90. &lt;br&gt;https://doi.org/10.1159/000500637</mixed-citation></ref><ref id="hanspub.42800-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Liang, K., Kandhare, A.D., Mukherjee-Kandhare, A.A., et al. (2019) Morin Ameliorates Ovalbumin-Induced Allergic rhinitis via Inhibition of STAT6/SOCS1 and GATA3/T-Bet Signaling Pathway in BALB/c Mice. Journal of Functional Foods, 55, 391-401. &lt;br&gt;https://doi.org/10.1016/j.jff.2019.01.052</mixed-citation></ref><ref id="hanspub.42800-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lin, H., Zheng, C., Li, J., et al. (2015) Lentiviral shRNA against KCa3.1 Inhibits Allergic Response in Allergic Rhinitis and Suppresses Mast Cell Activity via PI3K/AKT Signaling Pathway. Scientific Reports, 5, Article No. 13127.  
&lt;br&gt;https://doi.org/10.1038/srep13127</mixed-citation></ref></ref-list></back></article>